Phase I and pharmacokinetic study of OSI-211, a liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia.

被引：0
|
作者：
Giles, F
Tallman, M
Garcia-Manero, G
Cortes, J
Thomas, D
Wierda, W
Verstovsek, S
Hamilton, M
Barrett, E
Albitar, M
Kantarjian, H
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA
[3] OSI Pharmaceut Inc, Boulder, CO USA
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4732
引用
收藏
页码：251B / 251B
页数：1
相关论文
共 50 条
  • [21] Phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin
    R S de Jong
    N H Mulder
    D R A Uges
    D Th Sleijfer
    F J P Höppener
    H J M Groen
    P H B Willemse
    W T A van der Graaf
    E G E de Vries
    British Journal of Cancer, 1999, 79 : 882 - 887
  • [22] Phase I, Pharmacokinetic and Biological Correlative Study of OSI-7904L, a Novel Liposomal Thymidylate Synthase Inhibitor, and Cisplatin in Patients with Solid Tumors
    Ricart, Alejandro D.
    Berlin, Jordan D.
    Papadopoulos, Kyriakos P.
    Syed, Samira
    Drolet, Daniel W.
    Quaratino-Baker, Charlotte
    Horan, Julie
    Chick, Jon
    Vermeulen, Wendy
    Tolcher, Anthony W.
    Rowinsky, Eric K.
    Rothenberg, Mace L.
    CLINICAL CANCER RESEARCH, 2008, 14 (23) : 7947 - 7955
  • [23] Phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin
    de Jong, RS
    Mulder, NH
    Uges, DRA
    Sleijfer, DT
    Höppener, FJP
    Groen, HJM
    Willemse, PHB
    van der Graaf, WTA
    de Vries, EGE
    BRITISH JOURNAL OF CANCER, 1999, 79 (5-6) : 882 - 887
  • [24] Phase I study of clofarabine and liposomal daunorubicin in childhood acute myeloid leukemia.
    Kearns, P.
    Graham, N. J.
    Cummins, M.
    Gibson, B.
    Grainger, J. D.
    Keenan, R.
    Lancaster, D.
    Shenton, G.
    Vormoor, J.
    Webb, D.
    Hawley, I.
    Johnson, P. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [25] A phase I and pharmacokinetic study of rubitecan, an orally administered topoisomerase I (topo-I) inhibitor, combined with gemcitabine in patients with advanced cancer.
    Calvo, E
    Rowinsky, EK
    Tolcher, AW
    Chu, QS
    Beeram, M
    Forero, L
    Mettinger, KL
    Eastham, E
    Goetz, AD
    Patnaik, A
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 151S - 151S
  • [26] Phase I and Pharmacokinetic Study of Pegylated Liposomal CKD-602 in Patients with Advanced Malignancies
    Zamboni, William C.
    Ramalingam, Suresh
    Friedland, David M.
    Edwards, Robert P.
    Stoller, Ronald G.
    Strychor, Sandra
    Maruca, Lauren
    Zamboni, Beth A.
    Belani, Chandra P.
    Ramanathan, Ramesh K.
    CLINICAL CANCER RESEARCH, 2009, 15 (04) : 1466 - 1472
  • [27] Phase I pharmacokinetic study of a weekly liposomal paclitaxel formulation (Genexol®-PM) in patients with solid tumors
    Lim, W. T.
    Tan, E. H.
    Toh, C. K.
    Hee, S. W.
    Leong, S. S.
    Ang, P. C. S.
    Wong, N. S.
    Chowbay, B.
    ANNALS OF ONCOLOGY, 2010, 21 (02) : 382 - 388
  • [28] A phase I pharmacokinetic study of a liposomal formulation of paclitaxel administered weekly to Asian patients with solid malignancies
    Lim, W. T.
    Leong, S. S.
    Toh, C. K.
    Ang, C. S.
    Wong, N. S.
    Tan, E. H.
    Chowbay, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [29] A phase I study of the combination of a DNA topoisomerase inhibitor, idarubicin, with the histone deacetylase inhibitor vorinostat, in advanced acute leukemia
    Kadia, T. M.
    Borthakur, G.
    Wierda, W.
    Ravandi, F.
    Faderl, S.
    Newsome, W.
    Zwiebel, J.
    Egorin, M.
    Garcia-Manero, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [30] Phase I study of liposomal daunorubicin (daunoxome) in relapsed and refractory acute myeloid leukemia.
    Lerchenmüller, C
    Büchner, T
    Berdel, WE
    BLOOD, 1999, 94 (10) : 233B - 233B
12345